No Data
No Data
China TCM Holdings' H1 Profit Falls 64% as Revenue Slips 10%
Trad chi med (00570.HK): Traditional Chinese medicine 3.1 ancient classic prescription compound preparation Angelica blood-enriching soup granules approved for market.
Economic Daily 29th August|Traditional Chinese med (00570.HK) announced that the first traditional Chinese medicine compound preparation managed according to the ancient classic prescription catalogue (i.e., the 3.1 category new pharmaceutical of trad chi med) Angelica Sinensis Compound Granules ("the pharmaceutical") has been approved for marketing by the National Medical Products Administration of China, and the pharmaceutical marketing license holder is Guangdong Global Pharmaceutical Co., Ltd., an affiliate of the company. The pharmaceutical was independently developed by the group and the prescription originated from the "Identification of Internal and External Injuries." Angelica Sinensis Compound Granules ("the prescription") has the function of tonifying qi and nourishing blood, and it is the first domestically approved classic traditional Chinese medicine prescription based on this prescription. The approval and marketing of the pharmaceutical signifies the group's.
Express News | China Traditional Chinese Medicine - Danggui Buxue Tang Granules Approved for Marketing by Nmpa
trad chi med released its interim performance, with shareholders' share of net profit of 0.211 billion yuan, a year-on-year decrease of 63.5%.
Trad chi med (00570) released its interim performance for the six months ending June 30, 2024. The group achieved a total revenue of RMB 8.385 billion, a decrease of 9.9% year-on-year. The company's equity holders should account for a surplus of RMB 0.211 billion, a decrease of 63.5% year-on-year. Basic earnings per share were 4.19 cents.
Express News | China Traditional Chinese Medicine - Hy Profit Attributable RMB211 Mln
Express News | China Traditional Chinese Medicine Holdings - No Dividend Was Proposed for Six Months
No Data